Sensus Healthcare (SRTS)
Supplies superficial-radiation systems for non-melanoma skin cancer and keloid treatment.
$3.25
Pre-market−0.01 (−0.31%)
At close$3.26(−2.10%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4 | 13 | 11 | 9 | 9 | 13 | 8 | 7 | 7 | 5 | 3 | 2 |
| Cost of revenue | 2 | 5 | 4 | 4 | 4 | 6 | 4 | 4 | 4 | 3 | 2 | 2 |
| Gross profit | 2 | 8 | 7 | 5 | 5 | 7 | 4 | 3 | 3 | 2 | 1 | 1 |
| 4 | 2 | 4 | 3 | 4 | 5 | 7 | 5 | 5 | 5 | 5 | 4 | |
| Research & development | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 2 | 1 |
| 3 | 2 | 3 | 3 | 3 | 4 | 4 | 3 | 3 | 3 | 4 | 3 | |
| Selling & marketing | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 1 | 2 | 1 |
| General & administrative | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Operating income | −2 | 6 | 3 | 2 | 1 | 2 | −3 | −2 | −3 | −3 | −4 | −3 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −3 | 0 | 0 | 0 |
| Income before tax | −2 | 6 | 3 | 2 | 2 | 2 | −2 | −2 | −2 | −3 | −4 | −3 |
| Income tax expense | 0 | 2 | 1 | 1 | 1 | 0 | 0 | −1 | −1 | 0 | −2 | 6 |
| Net income from continuing operations | −1 | 4 | 2 | 2 | 1 | 2 | −3 | −1 | −1 | −3 | −3 | −9 |
| Net income | −1 | 4 | 2 | 2 | 1 | 2 | −3 | −1 | −1 | −3 | −3 | −9 |
| EPS, basic | −$0.09 | $0.26 | $0.14 | $0.10 | $0.07 | $0.09 | −$0.16 | −$0.06 | −$0.06 | −$0.19 | −$0.16 | −$0.53 |
| EPS, diluted | −$0.09 | $0.26 | $0.14 | $0.10 | $0.07 | $0.09 | −$0.16 | −$0.06 | −$0.06 | −$0.19 | −$0.16 | −$0.53 |
| Weighted average shares, basic | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Weighted average shares, diluted | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| EBITDA | −1 | 6 | 3 | 2 | 2 | 2 | −2 | −2 | 1 | −3 | −4 | −3 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −2 | 6 | 3 | 2 | 2 | 2 | −2 | −2 | 1 | −3 | −4 | −3 |